Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.61 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741253 | 0.89 | MEN1 (0.76) | RAB9ACNR1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3070329 | 0.89 | KMT2A (0.76) | RAB9APOLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL11048619 | 0.89 | MEN1 (0.76) | RAB9ACNR1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL30469243 | 0.83 | CNR1 (1.00) | CNR1 | |
| SCHEMBL20558081 | 0.83 | CNR1 (1.00) | CNR1 | |
| SCHEMBL3823913 | 0.82 | PTPN1 (0.73) | RAB9APOLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6415838 | 0.82 | PTPN1 (0.73) | RAB9APOLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL12218440 | 0.82 | RAB9A (0.79) | RAB9ACNR1KMT2ALMNAGRIK1 | |
| SCHEMBL11007034 | 0.82 | MEN1 (0.79) | RAB9APOLBCNR1KMT2ASMN1; SMN2 | |
| SCHEMBL9486165 | 0.82 | TP53 (0.74) | RAB9APOLBKMT2AMEN1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3894392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Duke University (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-9663452-B2 | Method for preparing formamidines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-05-30 | — | — | US | disclosed |
| US-9663452-B2 | Method for preparing formamidines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-05-30 | — | — | US | disclosed |
| US-20150266813-A1 | Method For Preparing Formamidines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266813-A1 | Method For Preparing Formamidines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885POLB 1149/4885CNR1 4359/4885 |
| US-20150266813-A1 | Method For Preparing Formamidines | PFAS, CYP4F3, CYP2F1 | RAB9A 217/4885POLB 3553/4885CNR1 3555/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885POLB 1149/4885CNR1 4359/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885POLB 1149/4885CNR1 4359/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885POLB 1149/4885CNR1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.